Genmab and PDL BioPharma, Inc. have entered into an agreement under which Genmab will acquire PDL’s antibody manufacturing facility in Brooklyn Park, MN, for $240 million in cash. The transaction includes land, equipment and access to a leased space with a development lab.             The facility has a production capacity of 22,000 liters, which the company expects will be sufficient to sustain both clinical and commercial scale material for its pipeline. The facility has two 1,000 lit...